Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody

Int J Cancer. 1994 Apr 1;57(1):10-4. doi: 10.1002/ijc.2910570103.


A human monoclonal anti-idiotypic antibody (105AD7) has been developed which mimics a colorectal-tumour-associated antigen and induces cellular anti-colorectal tumour immune responses in animals. Thirteen patients with advanced colorectal cancer were immunized with 105AD7 and their survival was compared with that of a contemporary group of unimmunized patients with similar disease status. No toxicity related to anti-idiotype immunization was seen. Cellular responses to anti-idiotypic immunization were indicated by lymphocyte proliferation to gp72-positive tumour cells, and production of interleukin-2; anti-tumour antibodies were not detected. Median survival following diagnosis of advanced disease of immunized patients was 12 months, compared with 4 months in unimmunized patients. The improved survival of immunized patients in this study without associated toxicity suggests that 105AD7 immunization may have considerable potential for immunotherapy of colorectal cancer.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Controlled Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Anti-Idiotypic / adverse effects
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Colorectal Neoplasms / immunology
  • Colorectal Neoplasms / therapy*
  • Female
  • Humans
  • Immunization*
  • Immunotherapy*
  • Male
  • Survival Analysis


  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal